Əsas səhifə

Çap

Əks əlaqə

İnfo
Botulinum toxin for the treatment of strabismus

Mündəricat

Botulinum toxin for the treatment of strabismus

Sübutlu məlumatların xülasələri
16.07.2017 • Sonuncu dəyişiklik 16.07.2017
Editors

There is insufficient evidence on the effectiveness of botulinum toxin for the treatment of strabismus.

A Cochrane review included 6 studies. Two trials conducted in Spain (102 people, number of eyes not specified) compared botulinum toxin with surgery in children that required retreatment for acquired or infantile esotropia. These two studies provided low-certainty evidence that children who received botulinum toxin may have a similar or slightly reduced chance of achieving ocular alignment (pooled risk ratio (RR) 0.91, 95% confidence interval (CI) 0.71 to 1.16), binocular single vision (RR 0.88, 95% CI 0.63 to 1.23), sensory fusion (RR 0.88, 95% CI 0.63 to 1.23) and stereopsis (RR 0.86, 95% CI 0.59 to 1.25) compared with children who received surgery. One trial from Canada compared botulinum toxin with surgery in 30 adults (30 eyes) with horizontal strabismus and reported a reduced chance of ocular alignment with botulinum toxin (RR 0.38, 95% CI 0.17 to 0.85; low-certainty evidence). One trial in the UK suggested that botulinum toxin may result in a similar or slightly improved chance of ocular alignment in people with acute onset sixth nerve palsy compared with observation (RR 1.19, 95% CI 0.96 to 1.48; 47 participants, low-certainty evidence). Very low-certainty evidence from one trial from Brazil suggested that adjuvant botulinum toxin in strabismus surgery may increase the chances of ocular alignment compared with strabismus surgery alone (RR 1.83, 95% CI 0.41 to 8.11; 23 participants). One trial from China of 47 participants (94 eyes) suggested that people receiving botulinum toxin combined with sodium hyaluronate may have a similar or slightly reduced chance of achieving ocular alignment compared with botulinum toxin alone (RR 0.81, 95% CI 0.36 to 1.82; low-certainty evidence). Reported complications in people given botulinum toxin in the included trials included ptosis (range 9% to 41.66%) and vertical deviation (range 8.3% to 18.51%). Ptosis occurred less frequently when treated with botulinum toxin combined with sodium hyaluronate compared to botulinum toxin alone.

Botulinum toxin showed no difference in response in comparison to surgery in patients who required retreatment for acquired esotropia or infantile esotropia and in whom there was potential for binocular vision. The studies defined a satisfactory outcome at one year follow-up as ≤ 8 prism dioptres (PD). In the study including children with infantile esotropia, this was achieved in 75% of the reoperation group and 67.85% of the botulinum toxin group. In the other study including children with acquired esotropia, this was achieved in 75% of the reoperation group and 69.56% of the botulinum toxin group. Botulinum toxin showed no difference compared to no treatment in acute sixth nerve palsy and thus was deemed to have no prophylactic effect in this condition. Full recovery was observed in 80% of control patients and 86% of botulinum toxin patients (the difference was not statistically significant). Botulinum toxin had a poorer response than surgery in a trial of patients requiring treatment for horizontal strabismus in the absence of binocular vision. A satisfactory outcome was defined as within 10 PD which was achieved in 76.9% of the surgery group and 29.4% in the botulinum toxin group (P = 0.027). Reported complications included ptosis and vertical deviation and ranged from 24% to 55.54%.

Comment: The quality of evidence is downgraded by study quality (inadequate allocation concealment), by inconsistency (variability in results across studies and heterogeneity in interventions and outcomes) and by imprecise results (limited study size for each comparison).

Ədəbiyyat

  1. Rowe FJ, Noonan CP. Botulinum toxin for the treatment of strabismus. Cochrane Database Syst Rev 2017;(3):CD006499.